Differential effects of complex II on mitochondrial ROS production and their relation to cardioprotective pre- and postconditioning  by Dröse, Stefan
Biochimica et Biophysica Acta 1827 (2013) 578–587
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbabioReview
Differential effects of complex II on mitochondrial ROS production and
their relation to cardioprotective pre- and postconditioning☆
Stefan Dröse ⁎
Molecular Bioenergetics Group, Medical School, Johann Wolfgang Goethe-Universität, Theodor-Stern Kai 7, Frankfurt am Main, GermanyAbbreviations: DLD, dihydrolipoamide dehydrogena
(mito)KATP, (mitochondrial) ATP-dependent K+ channel;
QFR, quinol:fumarate reductase; Qd site, distal ubiquinon
site, proximal ubiquinone binding site of complex II; Qi si
complex III; Qo site, ubiquinol oxidation site of complex III
ROS, reactive oxygen species; SDH, succinate dehydrogena
ticles; SQ, semiquinone; SQR, succinate:quinone oxidored
acid cycle; TTFA, 2-thenoyltriﬂuoroacetone
☆ This article is part of a Special Issue entitled: Respira
physiology and disease.
⁎ Klinik für Anästhesiologie, Intensivmedizin und Schm
Goethe-Universität, Frankfurt am Main, Germany. Tel.: +
69 6301 87822.
E-mail address: Stefan.Droese@kgu.de.
0005-2728/$ – see front matter © 2013 Elsevier B.V. Al
http://dx.doi.org/10.1016/j.bbabio.2013.01.004a b s t r a c ta r t i c l e i n f oArticle history:
Received 17 December 2012
Received in revised form 4 January 2013
Accepted 9 January 2013
Available online 16 January 2013
Keywords:
Complex II
Succinate:ubiquinone oxidoreductase
Mitochondria
Reactive oxygen species
Ischemic preconditioning
Pharmacological preconditioningThe production of reactive oxygen species by the mitochondrial complex II (succinate:ubiquinone oxidore-
ductase) recently has gained broad scientiﬁc interest. Depending on the (patho)physiological situation,
ROS produced or triggered by complex II can have either beneﬁcial or deleterious effects. This ambivalence
can be explained mechanistically by the diverse role of complex II on mitochondrial ROS production: it can
be a source as well as a suppressor or enhancer of ROS generation by other respiratory chain complexes.
Since complex II directly links the respiratory chain to the tricarboxylic acid (TCA) cycle, the TCA-cycle inter-
mediates – especially oxaloacetate that acts as a high afﬁnity endogenous inhibitor – have major impact on
complex II-related ROS release. The review relates the diverse effects of complex II activity on the mitochon-
drial ROS production that have been observed during cardioprotective ischemic or pharmacological
preconditioning and the oxidative burst that occurs during ischemia/reperfusion. This article is part of a Spe-
cial Issue entitled: Respiratory complex II: Role in cellular physiology and disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial complex II (succinate:ubiquinone oxidoreductase;
succinate dehydrogenase, SDH) oxidizes succinate to fumarate and
reduces ubiquinone, thereby creating a direct link between the tri-
carboxylic acid (TCA) cycle (also known as citric acid or Krebs
cycle) and the respiratory chain [1] (Fig. 1). The respiratory chain
provides the main portion of ATP in eukaryotic cells, but is also a
major source of reactive oxygen species (ROS) [2–6]. An increased
mitochondrial ROS production has been associated with numerous
pathophysiological settings including neurodegenerative diseases [7],
oxidative damage during ischemia/reperfusion injury [8,9] and the
aging process [10,11]. Within the respiratory chain, complexes I
(NADH:ubiquinone oxidoreductase) and III (ubiquinol:cytochrome c
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l rights reserved.the main ROS sources, while the contribution of intact complex II
seems to be negligible [3–6]. However, some mutations in complex II
subunits that have been linked to speciﬁc forms of cancer or
neurodegeneration can lead to an increased ROS generation (reviewed
in [12–14]). Furthermore, it is well known that complex II activity can
have major impact on the ROS production by complexes I and III
[15,16]. With isolated mitochondria it has been shown that a high suc-
cinate concentration and a high membrane potential induce reverse
electron transfer from complex II into complex I that is associated
with a high rate of superoxide production [17–23]. Under these condi-
tions inhibition of complex II leads to a reduction of complex I related
ROS generation [15,16,19,20,24]. On the other hand, inhibition of com-
plex II can increase the generation of superoxide at the ubiquinol oxida-
tion site (Qo site) of complex III under speciﬁc conditions [25], i.e.when
succinate is the predominant substrate and when the electron transfer
between heme bL (low potential heme) and heme bH (high potential
heme) is slowed down additionally, e.g.when the ubiquinone reduction
site of complex III (Qi site) is blocked by inhibitors like antimycin A
[15,16,26–31]. This ROS-promoting effect of complex II inhibitors can
be related to a partially oxidized Q-pool thatmaximizes ROS production
by complex III upon antimycin inhibition [25,32,33]. In addition, it has
been proposed that complex II controls mitochondrial ROS production
via a succinate-dependent interaction with complex I [34,35] or that
complex II per se is a major source of ROS which under physiological
conditions is linked to disease scenarios such as cancers or tissue dam-
age associated with oxidative stress [36]. Very recently, Quinlan and
colleagues could show that mitochondrial complex II can indeed pro-
duce high levels of ROS when (i) succinate concentration is low and
Fig. 1. Complex II links the respiratory chain to the TCA cycle. Complex II oxidizes succinate to fumarate and transfers two electrons onto ubiquinone that fuels the respiratory chain
complexes III and IV (not shown). The activity of complex II is regulated by the concentration of succinate and some intermediates of the TCA cycle (especially oxaloacetate), that
have been shown to competitively inhibit complex II (indicated by a circled minus sign; the size of the sign reﬂects the inhibitor potency). The activity can also be positively reg-
ulated (indicated by a circled plus sign) by (1) acetyl-CoA generation reactions that will promote removal of accumulated oxaloacetate, which in turn releases complex II inhibition.
And (2) by inhibition of complex I, since this will shift the NADH/NAD+ ratio completely to the reduced form and oxaloacetate can no longer be generated from malate.
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curs [37]. Hence, it is not surprising that complex II inhibitors show am-
bivalent effects onmitochondrial ROS production [15,16] depending on
substrate supply, membrane potential and overall activities of respira-
tory chain and TCA cycle enzymes.
An ambivalence of mitochondrial ROS production has been also
detected in the context of ischemia/reperfusion and ischemic or
pharmacological preconditioning: while reactive oxygen species
are among the main determinants of cellular damage during longer
periods of ischemia and reperfusion, there is also ample evidence
that mitochondrial ROS production is involved in cardioprotective
signaling during ischemic and pharmacological preconditioning
(overviews in [8,38–40]). In this context, complex II inhibitors have
been shown to exert protective effects in different model systems
during preconditioning phases or when they were present during re-
perfusion [41–44]. It has been proposed that the production of ‘dele-
terious ROS’ during reperfusion can be related to complex I, while
the generation of ‘signaling ROS’ during preconditioning occurs at
the Qo site of complex III [15]. The protective effects of complex II in-
hibitors could then be explained by their differential effects on com-
plex I and complex III related ROS production: they reduce ROS that
are generated at complex I by reverse electron transfer (RET) during
reperfusion while they promote production of ROS at the Qo site of
complex III by shifting the redox state of the Q-pool to an intermedi-
ate state [15]. This review intends to summarize the intricate inﬂu-
ence of complex II on mitochondrial ROS production and its
relation to ischemia/reperfusion and preconditioning.
2. Composition, catalytic activity and physiological function of
mitochondrial complex II
Mitochondrial complex II is unique among the respiratory chain
complexes in several ways: it does not contribute directly to the gen-
eration of the proton motive force (however it contributes to the re-
duction of ubiquinone to ubiquinol that fuels the downstreamcomplexes III and IV), it does not contain subunits that are encoded
by mitochondrial DNA and it is an indispensable component of an-
other major energy-converting pathway, the TCA cycle. In addition,
mitochondrial respiratory chain complexes I, III and IV are organized
in ‘supercomplexes’ or ‘respirasomes’, whereas complex II was identi-
ﬁed as an isolated entity in mildly solubilized mitochondrial mem-
branes [45–47]. One report implicates that complex II is associated
with ‘supercomplexes’ [48], but a detailed analysis of the complexome
of puriﬁed rat heart mitochondria did not conﬁrm an association of
complex II with other respiratory chain complexes [49].2.1. Subunit composition and redox groups
Mitochondrial as well as bacterial succinate:quinone oxidoreduc-
tases (SQRs) catalyze the oxidation of succinate to fumarate and
transfer the two electrons derived from this reaction via four pros-
thetic redox-groups (one covalently bound ﬂavin adenine dinucleo-
tide (FAD) asnd three iron–sulfur clusters) onto membrane-bound
ubiquinone under aerobic conditions [1,50,51]. The structural orga-
nization of complex II is well known (for recent reviews see
[14,52]), since the X-ray crystal structures of the enzymes from
Escherichia coli [12,53,54], as well as porcine [55] and avian [56] mi-
tochondria have been determined. In addition, the structures of
closely related bacterial fumarate reductases (quinol:fumarate re-
ductases, QFRs) [57,58] and further members of the ‘complex II su-
perfamily’ have been solved (overview in [52], this issue). In
bacteria, fumarate reductase replaces the succinate:quinone oxidore-
ductase under anaerobic conditions [59,60]. In E. coli, SQR and QFR are
capable of replacing each other functionally in vivo i.e.both catalyze suc-
cinate oxidation and fumarate reduction, albeit with different afﬁnities
and catalytic rates [52]. It is important to note that the overall structural
and functional similarity of E. coli SQR and QFR to mammalian complex
II has made them useful models systems for structure–function investi-
gations and the analysis of disease-related human mutations [14].
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a ﬂavoprotein SdhA and an iron–sulfur protein subunit (SdhB), and
two hydrophobic membrane anchored subunits (SdhC, SdhD),
which contain one heme b and the binding site(s) for ubiquinone
[12,14,52,55,56] (Fig. 2A). However, a number of bacterial SQRs
(e.g. the Gram-positive Bacillus subtilis) only have a single membrane
anchor subunit [1,50]. SdhA is the largest subunit and contains a co-
valently attached FAD in the dicarboxylate binding site, where succi-
nate is oxidized to fumarate. SdhB contains three linearly aligned
iron–sulfur clusters (in the order 2Fe–2S, 4Fe–4S, 3Fe–4S towards
the membrane) that transfer the electrons derived from succinate oxi-
dation to the ubiquinone binding site located at the interface of SdhB
and the integral membrane proteins SdhC and SdhD. In addition to
this ‘proximal’ Q-binding site (Qp), a second ‘distal’ Q-binding site
(Qd) near the intermembrane space side has been proposed based on
biochemical studies [50] and co-crystals of the porcine complex II
with the competitive Q-site inhibitor TTFA [55]. However, the function-
al signiﬁcance of these ﬁndings has been questioned [51]. SdhC and
SdhD contain a b-type heme that is located off-pathway from the elec-
tron transferring cofactors and does not contribute to the electronFig. 2. Structure and function of complex II. A) Composition and arrangement of redox
centers. The four subunits (Sdh A-D) are indicated by capital letters, the relative po-
sitions of the prosthetic groups are indicated as black circles ([FeS]-clusters), a tricy-
clic structure (FAD), a stretched hexagon (Qp site) and a schematic porphyrin ring
(heme b). The structures and binding sites of some inhibitors mentioned in this review
are also indicated. B) Electron transfer and potential sources of ROSwithin complex II. In-
termediates thatwere shown or have the potential to produce reactive oxygen species are
highlighted by a star-shaped edge. Electron transfer reactions are indicated by dotted ar-
rows. 2 e−, indicates a sequential or concerted transfer of two electrons; 2×, indicates that
the path through the iron–sulfur clusters (black circles) subsequently transfers two single
electrons – the ﬁrst supplied by the fully reduced ﬂavin, the second by the FAD
semiquinone (FADH•) – stepwise to ubiquinone (Q), yielding semiquinone (SQ•) and
ubiquinol (QH2), respectively. For details, see text.transfer between the two substrate binding sites [12,52]. Since both
FAD semiquinone [61,62] as well as ubisemiquinone radicals [63,64],
have been detected by EPR, a stepwise removal of electrons from succi-
nate followed by a stepwise electron transfer onto ubiquinone can be
deduced.
2.2. Complex II links the TCA cycle to the respiratory chain
As a component of the respiratory chain and the TCA cycle complex II
provides a direct link between these two major energy-converting path-
ways in the mitochondria (and bacteria). Besides the supply of electrons
for the respiratory chain, the TCA cycle also provides precursors and
redox equivalents for the synthesis of various organic substances includ-
ing certain amino acids. Since several catabolic pathways converge on
the TCA cycle, it is the ﬁnal common pathway for providing energy
from carbohydrates, fatty acids and proteins and as such requires a strict
regulation. The activity of the eight enzymes involved is regulated by the
general metabolic situation (i.e. energy charge) and the concentration of
the respective metabolites that are controlled by the enzyme activities,
anaplerotic reactions and the activity of speciﬁc transporters located in
the inner mitochondrial membrane (Fig. 1). The activity of complex II is
directly inﬂuenced by the concentration of other TCA cycle metabolites,
since malate, fumarate, citrate and especially oxaloacetate [65–67] have
been shown to inhibit competitivelywith succinate. Besides a direct com-
petition between succinate and malate, it has been observed that
complex II can oxidize malate to the enol form oxaloacetate
[67,68], which binds to the dicarboxylate binding site with high af-
ﬁnity [66]. Oxaloacetate formation is also the reason why succinate
alone is only supporting weak state 3 respiration of isolated mito-
chondria [65]. However, oxaloacetate formation can be indirectly
suppressed by the addition of complex I inhibitors like rotenone
that block reoxidation of NADH to NAD+ thereby preventing the ox-
idation of malate by the malate dehydrogenase. On the other hand,
uncouplers and other factors that impede the removal of accumulat-
ed oxaloacetate can also reduce succinate supported respiration [69].
Another important factor that determines complex II activity is the
succinate concentration itself. The Km values of complex II and the
dicarboxylate carrier that catalyzes transport of succinate into the
mitochondria are around 1 mM [70,71]. The succinate concentration
in different tissues and mitochondria is in the submillimolar range
under aerobic conditions [22,72,73], indicating that complex II is
not working at maximal velocity under ‘standard conditions’. How-
ever, several studies have shown that the succinate concentration in-
creases under hypoxic conditions up to values of several millimolar
[22,72,74–78]. This increased succinate pool under hypoxia might
be supplied either from glutamate throughα-ketoglutarate by trans-
amination [76,77] or by a partial reversal of the TCA cycle from ma-
late through fumarate, which requires that complex II would
become a fumarate reductase under hypoxia [36,79].
2.3. Inhibitors of complex II
Inhibitors of respiratory chain complexes have proven to be useful
tools for investigations of their functions and mechanisms, including
the production of reactive oxygen species. Speciﬁc inhibitors of complex
II can be divided into two subgroups: (i) inhibitors that bind to the car-
boxylate (succinate) binding site and (ii) inhibitors that bind to the Q
site (Fig. 2A). The ﬁrst group comprises molecules that structurally re-
semble succinate (overview in [14]) including the above mentioned
oxaloactate, malonate and the toxin 3-nitropropionate [80], that has
also been used for co-crystallization with complex II from porcine
heart mitochondria [55]. This complex II has also been co-crystallized
with the TTFA (2-thenoyltriﬂuoroacetone), a well known inhibitor of
the Q-binding site [81,82]. TTFA binds to the Qp site close to the matrix
and to a putative second ubiquinone binding site (Qd) [55], whose func-
tional signiﬁcance has been questioned [51]. Themost potent inhibitors
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bind to the Qp site [53]. Another interesting group of complex II Q-site
inhibitors are vitamin E analogues, including α-tocopheryl succinate
(α-TOS) [85] and MitoVES (mitochondrially targeted vitamin E succi-
nate) [86,87] that have been used in model systems to speciﬁcally in-
duce cell death of cancer cells. Covering this topic is beyond the scope
of this review and the interested reader is referred to recent overviews
[36,88]. Furthermore, complex II activity can also be regulated by post-
translational modiﬁcation, e.g. by acetylation of lysine residues that is
controlled by the activity of the mitochondrial NAD-dependent
deacetylase SIRT 3 [89,90].
3. Complex II and reactive oxygen species, a complex scenario
3.1. Complex II as a source of ROS
Up to the recently published investigation by Quinlan and col-
leagues [37], intact mammalian complex II has hardly been recog-
nized as a major source of ROS [3–6]. In most studies with isolated
mitochondria and submitochondrial particles (SMP), a saturating
succinate concentration (usually around 5 mM) has been applied.
In coupled mitochondria and SMP, high ROS production is observed
under these conditions, but this can be largely attributed to complex
I due to reverse electron transfer from complex II, since (i) it is sen-
sitive to complex I inhibitors like rotenone [18–20,24,91,92], (ii) re-
quires a high membrane potential, i.e. is sensitive to uncouplers and
ionophores [15,18–20,91] or ADP (that induces state 3 respiration)
[17], and (iii) does not occur in uncoupled submitochondrial parti-
cles (SMP) [32,93]. This was also conﬁrmed by Quinlan et al. [37],
however these authors also observed that complex II in isolated rat
skeletal mitochondria produced ROS at a signiﬁcant rate with succi-
nate concentrations below 5 mM (with a peak at around 400 μM)
and when the downstream respiratory chain was inhibited. A signif-
icant contribution of complexes I and III to the detected ROS genera-
tion could be excluded by the addition of rotenone (that inhibits ROS
production by RET at complex I) and myxothiazol (that inhibits ROS
production at the Qo site of complex III and at the same time served
as the downstream block). At succinate concentrations below
400 μM, ROS production decreased again. Furthermore, this ROS pro-
duction was completely sensitive to the competitive carboxylate site
inhibitor malonate and was only partially repressed by the Q-site in-
hibitor atpenin A5. Therefore, the authors concluded that the ROS
must have been produced at the ﬂavin site of complex II [37]. Fur-
thermore, Quinlan et al. could show that complex II also produced
ROS in the reverse reaction, i.e. when the electrons are provided
from the reduced ubiquinone pool [37]. They proposed a mechanism
for ROS production by complex II that relies upon the occupancy of
the carboxylate binding site and the reduction state of the enzyme,
i.e. ROS are only generated when the ﬂavin is reduced and the car-
boxylate binding site is not occupied. Finally, it was shown that the
complex II related rates approach or exceed the maximum rates of
complexes I and III indicating that complex II may be an important
contributor to physiological and pathological ROS production [37].
It has been observed that loss of function of complex II can lead
to the accumulation of succinate and increased ROS generation in
mammalian cells (overview in [14,36]). This seems to be especially
the case for mutations in complex II subunits C and D located in the
vicinity of the Qp site that have been associated with speciﬁc forms
of cancer such as hereditary paragangliomas and pheochromocyto-
mas (overview in [13,14,36]) and in SdhA that can cause Leigh syn-
drome, a progressive neurodegenerative disease [14,94]. However,
investigations showing unambiguously that a disease associated
mutation directly causes an increased ROS generation by mamma-
lian complex II are scarce. Ishii and coworkers observed that a mu-
tation in the SdhC subunit in transgenic mouse ﬁbroblasts and
conditional transgenic mice induces mitochondrial respiratorychain dysfunction and increased ROS production [95]. However,
conclusive experiments that would exclude other respiratory
chain complexes or matrix dehydrogenases as ROS source are not
shown. This also applies to an investigation that revealed an in-
creased ROS production by a SdhD mutant in hamster ﬁbroblasts
[96]. Ishii and coworkers have used non-mammalian model organ-
isms for the analysis of oxidative stress associated with complex II
mutations (overview in [97]). They found that a mutation in SdhC
in complex II from Caenorhabditis elegans (mev-1(kn1)) caused hy-
persensitivity to increased oxygen concentrations [98] and in-
duced an increased ROS production [99] that was observed in
succinate-fueled mitochondria and SMP from the (mev-1(kn1))
mutant [99]. The experiments with (most likely uncoupled) SMP
largely exclude that the observed ROS production was due to
RET-induced superoxide production by complex I. A detailed inves-
tigation was performed with complex II from the parasitic hel-
minth Ascaris suum that functions in adult worms as the terminal
oxidase of the anaerobic respiratory chain and catalyzes fumarate
reduction [100]. The succinate-dependent ROS generation of SMP
from adult worms, that do not contain complex III and IV activities
in their respiratory chain, was not inﬂuenced by a complex I inhib-
itor and was completely and partially suppressed by malonate or
atpenin A5, respectively. This indicates that complex II is the exclu-
sive ROS source under these conditions. Also the ROS generation of
succinate-fueled SMP from A. suum L3 larvae, that contain a respira-
tory chain similar to mammalian mitochondria, was only affected
by complex II inhibitors and not by inhibitors of the other respira-
tory chain complexes.
Detailed analysis of the ROS production has also been performed
with bacterial SQRs and QFRs from E. coli [101] featuring structural
and functional similarity to mammalian complex II [14]. Both enzymes
produced ROS with a linear dependence on the dissolved oxygen con-
centration, although SQR produced ROS at a much lower rate. Further-
more, both enzymes showed maximal rates of ROS at intermediate
succinate concentrations between 0.1 and 1 mM and decreased rates
at lower and higher substrate concentration, which resembles the de-
pendence found later formammalian [37] and nematode [100] complex
II. E. coli SQR exclusively produces superoxide. In contrast, E. coli QFR
produces mainly superoxide at lower succinate concentrations and
comparably more hydrogen peroxide at higher substrate concentra-
tions [101]. A similar effect was observed in amutant containing a prox-
imal [2Fe–2S] cluster with lower redox potential. Messner and Imlay
concluded that QFR releases superoxide from the fully reduced ﬂavin
if the [2Fe–2S] cluster is available to sequester the semiquinone elec-
tron; otherwise this electron is rapidly transferred to the nascent super-
oxide and hydrogen peroxide is released [101]. Yankovskaya et al. [12]
proposed that the key difference in the ROS production by E. coli
SQR and QFR lies in the differential arrangement of redox poten-
tials among the redox centers. In SQR the high potential centers
([3Fe–4S] and heme b, which attract electrons and pull them
away from the dicarboxylate site) are close to the Q site, while in
QFR, FAD and the [2Fe–2S] clusters have the highest redox poten-
tials and hence accumulate electrons close to the dicarboxylate
binding site. While these arrangements favor the respective phys-
iological activity (i.e., ubiquinone reduction for SQR and fumarate
reduction/menaquinol oxidation for QFR) they also presuppose a
differential disposition for superoxide production under aerobic
conditions. This suggests that an increased reduction of FAD in the
dicarboxylate binding site – either by differential intrinsic properties
and arrangements of the redox centers, or mutations/inhibition of down-
stream located redox centers – causes an increased risk for ROS produc-
tion under aerobic conditions. Mutants of E. coli SQR that do not contain
heme b showed an unchanged ROS generation, indicating that this pros-
thetic group is not serving as a ‘sink’ for excess electrons [102,103].
There is an ongoing discussion whether the Q site or the FAD is the
primary source of ROS within complex II. As mentioned above (Section
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by EPR, which are both in principle suitable as electron sources for the
generation of superoxide (Fig. 2B). The Q site has been proposed as the
site of ROS production based on studies in Saccharomyces cerevisae
[104,105] and a mixed contribution of FAD and Q site was suggested
for complex II from A. suum [100]. While a contribution of the Q site
might occur in the respective mutants, the most likely source of ROS in
wild-type complex II is the fully reduced FAD [37,101]. Especially the
suppression of ROS generation by higher substrate concentrations
(which leaves the redox state of the redox centers largely unaffected)
strengthens the latter model indicating that complex II generates ROS
when the FAD is reduced and the dicarboxylate binding site is not occu-
pied. In principle, fully reduced FAD caneither transfer one electron onto
molecular oxygenwhich leads to the formation of superoxide (probably
the major reaction in complex II, but only conﬁrmed for E. coli SQR
[101]) or it may also transfer both electrons onto O2 which leads to the
formation of H2O2 (as shown for E. coli QFR [101]) (Fig. 2B). FAD is
also supported as the primary ROS source by studies with Q-site inhibi-
tors like α-TOS or MitoVES that induce an increased ROS generation
linked to selective cell death in some cancer forms [85–87,106] (detailed
overview in [36]). A ROS production at the Q site should rather be
blocked by these inhibitors, which leaves only the FAD as the redox
group involved — provided that complex II is indeed the ROS source
under the applied conditions. It has to be noted that this class of inhibi-
tors only functions in cancer cells with an unaffected ubiquinone bind-
ing ability of complex II [85–87].
3.2. Complex II as a modulator of the ROS production by complexes I and
III
Apart from the direct generation of ROS (Section 3.1), complex II has
been recognized as a modulator of the superoxide production by other
mitochondrial enzymes, especially the respiratory chain complexes I
and III [15,16,25] that are generally regarded as main ROS sources in
the mitochondria [3–6]. It is well known that isolated mitochondria
produce large quantities of ROSwhen they are incubatedwith succinate
as the sole or equally supplied substrate source [17–23]. Under some
speciﬁc conditions (i.e. in presence of pyruvate and glutamate), a sup-
plementation of only 15–150 μM succinate is enough to increase ROS
release from isolated mitochondria signiﬁcantly [34]. While alternative
explanations for the source or mechanism of ROS production under
these conditions have been proposed [34,36], the prevalent view is
that under these conditions ROS are produced by complex I due to
RET from complex II [18–20,23]. Whereas a contribution of other com-
ponents – especially the DLD (dihydrolipoamide dehydrogenase) com-
ponent of pyruvate dehydrogenase andα-ketoglutarate dehydrogenase
[22,107] – cannot be excluded, the strongest argument for the ‘ROS by
RET’ hypothesis is that ROS production is highly sensitive to even
small changes in membrane potential [18]. In a detailed analysis,
Votyakova and Reynolds determined that a drop in ΔΨ by only 5% re-
duces the hydrogen peroxide release of isolated mitochondria by 95%.
This indicates that a large membrane potential is prerequisite to drive
the electrons against the gradient of redox potentials from complex II
into complex I. Furthermore, investigationswith different experimental
systems (intact mitochondria and coupled SMP) revealed that different
complex I inhibitors like the Q-site inhibitor rotenone or inhibitors that
compromise the primary electron acceptor FMN or the NADH binding
site suppressed ROS generation under conditions of reverse electron
transfer [18–20,24,91,92]. The ROS production is also attenuated by
complex II inhibitors that bind either to the dicarboxylate site or the
Qp site if succinate is the prevalent substrate [15,16,19,20,24]. Under
these conditions complex II activity is necessary for the reduction of
ubiquinol that fuels the respiratory chain complexes III and IV to gener-
ate the proton-motive force that is required for RET (Fig. 3A). Inhibition
of complex II reduces the membrane potential by diminishing the elec-
tron supply for the downstream respiratory chain complexes. A highrate of ROS production is also observed when NADH-generating sub-
strates and succinate are concomitantly supplied to isolated mitochon-
dria [21,23,34,35]. Zoccarato and colleagues have shown that under
these conditions electrons can ﬂow downstream through complex I,
which should attenuate RET [21]. Accordingly, they have suggested
that the ROS production is not realized by RET, but by a direct interac-
tion between complexes I and II. However, such a speciﬁc interaction
still has to be demonstrated. Furthermore, other studies demonstrated
that different NADH-generating substrates have an opposing effect on
ROS generation [23,35,108] and it was suggested by Muller et al. that
the differential contribution of TCA cycle enzymes and the conditional
removal of the endogenous complex II inhibitor oxaloacetate are key
factors that control succinate-dependent ROS generation [23]. They
have proposed that the reduction of the succinate-dependent ROS for-
mation by malate is due to an accumulation of oxaloacetate that occurs
unless acetyl-CoA is available. Furthermore, it can be concluded that the
oxaloacetate inhibition of complex II has developed as a mechanism to
minimize RET-mediated superoxide production [23]. However, experi-
mental evidence for an oxaloacetate-dependent inhibition of complex II
under anoxic conditions is lacking [109].
Under very speciﬁc conditions, complex II can also modulate the su-
peroxide production at the Qo site of complex III [15,16,33] (Fig. 3B).
One prerequisite for this is that succinate is the predominate substrate,
another that conditions of ‘oxidant-induced reductions’ are applied to
complex III. Experimentally, this can be achieved by the addition of
the Qi site inhibitor antimycin A, but a corresponding physiological sce-
nario has not been identiﬁed yet. Anyway, the reduction of complex II
activity leads to an increase of the ROS generation by the antimycin
A-inhibited complex III [15,16,26–31,33]. This can be explained by an
increased oxidation of the Q-pool, since it was shown that the superox-
ide generation at the Qo site ismaximal at intermediate reduction states
of the ubiquinone pool if theQi site is blocked by antimycin A [25,32,33].
In summary, the differential effects of complex II on mitochondrial
ROS production seem to be inﬂuenced by the succinate concentration
and the activity of the other respiratory chain complexes. It can be
assessed by the distinct effects of complex II inhibitors (Fig. 3). Complex
II predominantly produces ROS from reduced FAD at low succinate con-
centrations and when the downstream electron transfer chain is
blocked (Fig. 3C). The block can occur either at the Qp site or further
downstream, e.g. at the Qo site of complex III. Also inhibition of the Qi
site by antimycin A should increase ROS generation by complex II
under these conditions, but this will be not immediately evident since
antimycin Awill also induce superoxide at the Qo site of complex III. Im-
portantly, inhibitors of the dicarboxylate binding sitewill attenuate ROS
production at complex II. In this regard, oxaloacetate could act as a
physiological suppressor or regulator of the ROS production by complex
II. In contrast, Qp site inhibitors will induce ROS production at low suc-
cinate concentrations. However, atpenin A5 induced ROS generation by
complex II was somewhat lower than ROS generation induced by a fur-
ther downstream block (at the complex III Qo site by myxothialzol),
which has been explained by an alteration of the succinate dehydro-
genase activity upon atpenin A5 binding [37]. A high succinate con-
centration and elevated complex II activity will suppress ROS
generation from FAD, but will induce superoxide production at com-
plex I due to RET (Fig. 3A). The activities of complexes III and IV are
necessary for the generation of a high membrane potential that is
prerequisite for ROS by RET. This has not been considered in recent
publications that have challenged the existence of a reverse electron
transfer from complex II into complex I [36,110]. ROS production
under these conditions is therefore not only attenuated by both clas-
ses of complex II inhibitors, but also by uncouplers, ionophores and
complex I inhibitors. Also complex III inhibitors like stigmatellin,
myxothiazol or antimycin A will inhibit succinate-dependent ROS
by RET, because the membrane potential collapses upon complex
III inhibition. However, inhibition by antimycin A will increase the
superoxide generation at the Qo site. Hence, the overall ROS release
Fig. 3. Differential effects of complex II on the mitochondrial ROS production. The succinate concentration/complex II activity that promotes the respective mode of action and the
effect of the two groups of complex II inhibitors are indicated below the schematic representation of the respiratory chain complexes involved. [FeS]-clusters are shown as black
circles, ubiquinone binding sites are stretched hexagons, heme groups as schematic porphyrins. Other factors inﬂuencing ROS production are highlighted by white boxes. A stop
sign indicates a requirement for a downstream block in the electron transfer chain. A) At high succinate concentrations, ROS are generated at complex I due to reverse electron
transfer (RET) from complex II. This requires the activity of complexes III and IV for the generation of a high membrane potential (ΔΨ). Potential sites that generate superoxide
are either the FMN or the Q-binding site of complex I. B) Under conditions of ‘oxidant-induced reduction’, a moderate complex II activity stimulates superoxide production at
the Qo site of antimycin A inhibited complex III, which is favored by a partially oxidized Q-pool (for details see text). C) Complex II produces ROS (presumably mainly superoxide)
at low succinate concentrations and when the electron transfer to the Qp site is inhibited/slowed down, which can be attained by Qp-site inhibitors like atpenin A5 or TTFA or by a
block located further downstream (e.g. at complex III). Under these conditions, ROS are produced from the ﬂavin site. Some mutations in the Qp site might also cause increased ROS
generation from this site (not shown, for details see text).
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ROS production is shifted from complex I to complex III. Finally, both
classes of complex II inhibitors will increase superoxide production
at the Qo site of complex III under conditions of ‘oxidant-induced re-
duction’, i.e.when the Qi site of complex III is blocked and when suc-
cinate is the predominate substrate (Fig. 3B). Under these speciﬁc
conditions, an intermediate succinate concentration/complex II ac-
tivity results in an intermediate reduction of the Q-pool that favors
superoxide production by complex III [32].
3.3. Complex II and the antioxidative defense
Recent investigations indicate that mitochondria are not only an
important source of ROS, but can also scavenge large quantities of in-
ternally and externally produced reactive oxygen species, especially
hydrogen peroxide [22,111–116]. Therefore, it has been proposed
that mitochondria are rather a sink for cellular ROS than a main pro-
ducer [22]. The highly effective mitochondrial antioxidative defense
system encompasses the thioredoxin/peroxiredoxin system as well
as the glutathione/glutathione peroxidase system (overview in
[22,117]). In mammalian cells, these two major antioxidative de-
fense systems rely on the availability of NADPH. In this context, it is
important to note that the H2O2 scavenger activities of isolated mito-
chondria are lower with succinate as the sole substrate than with
NADH-generating substrates like malate/glutamate or malate/pyruvate
[111,112]. This might be explained by the fact that one of the main
NADP+-reducing enzymes in the mitochondria, the membrane-bound
transhydrogenase [118], depends on a constant NADH supply. Alterna-
tively, the substrate ﬂow through the TCA cycle differs depending on
the substrates, which might affect the activity of the other twomitochondrial NADPH-regenerating enzymes the NADP+-dependent
isocitrate dehydrogenase [119,120] and the malic enzyme [118,121].
While in vivo succinate will hardly be the only available substrate in
the mitochondria, the differential ROS scavenger activities with differ-
ent substrates have certainly an impact on in vitro investigations with
isolated mitochondria.
4. Modulation of complex II activity in the context of cardioprotective
pre- and postconditioning
4.1. Brief introduction to ischemia/reperfusion and the phenomena of
pre- and postconditioning
It is well known that a prolonged period of ischemia followed by re-
perfusion irreversibly damages the heart and other tissues (overview in
[8,9]). Mitochondria seem to play a central role in reperfusion injury,
since the induction of the mitochondrial permeability transition pore
(mPTP) upon calcium-overload and oxidative stress leads ﬁnally to ap-
optotic and necrotic cell death [8,122]. It has been recognized that the
mitochondria are both targets and sources of injury during cardiac is-
chemia and reperfusion [123]. However, the damage occurring during
ischemia/reperfusion (I/R) can be reduced by ischemic preconditioning
where the prolonged ischemic period is preceded by one or more brief
(2–5 min) cycles of ischemia and reperfusion [8,39,124]. Ischemic
preconditioning can bemimicked by the KATP channel opener diazoxide
and various other substances, a phenomenon termed pharmacological
preconditioning [39]. Diazoxide as well as several very brief ischemic
intervals (10 s) during the early phase of reperfusion also improve the
recovery of the heart and reduce infarct size, a phenomenon termed
postconditioning [8]. Covering all aspects of this extensive topic is
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complex II in the generation of mitochondrial ROS during reperfusion,
pre- and postconditioning.4.2. Ambivalent roles of complex II and ROS in cardioprotective
preconditioning and I/R injury
Reactive oxygen species are a main factor contributing to the
damage during I/R [8]. During ischemia, only a small increase of
ROS has been detected, but a burst occurs upon reperfusion
[43,125]. The source of these ROS is still a matter of debate [8,123].
Considering the accumulation of succinate under hypoxic/ischemic
conditions (Section 2.2), the RET-dependent ROS production by
complex I seems to be a likely candidate (Fig. 3A). Chen and col-
leagues summarized how respiratory chain-modulating substances
protect cardiac mitochondria and decrease myocardial injury during
ischemia and reperfusion [123]. They identiﬁed uncouplers and
complex I inhibitors as compounds that attenuate the ROS-induced
damage in I/R-hearts. It seems plausible that both substance groups
exert their protective effects by suppressing the RET-induced super-
oxide production by complex I (Section 3.2), but Chen et al.
suggested complex III as the source of ROS [123]. Anyway, there is
also evidence that complex II inhibitors can suppress the oxidative
burst when they are present during reperfusion, which can be relat-
ed to postconditioning. It has been shown that malonate and
diazoxide, a well known opener of ATP-gated K+-channels (KATP
channels), can attenuate the ROS generation that occurs after and
during an ischemic period and upon reperfusion in isolated rat
heart mitochondria [41–43]. In addition to the interaction with
KATP channels, diazoxide has been shown to inhibit mitochondrial
complex II [15,126–129]. Accordingly, inhibition of complex II and
attenuation of the succinate supported ROS generation have been
shown by Dzeja et al. [130]. Mechanistically, the ROS-reducing prop-
erties of complex II inhibitors during reperfusion might be explained
by the reduction of the membrane potential (Fig. 3A) that is required
for the generation of superoxide at complex I via reverse electron
transfer. Such a mechanism is supported by several studies with iso-
lated mitochondria [15,16,19,20,24].
Diazoxide and other complex II inhibitors like malonate and
atpenin A 5 can also exert protective effects in different model sys-
tems (isolated cardiomyocytes, Langendorff-perfused rat hearts)
when they are added prior to the long damage-inducing ischemic/
reperfusion period [42–44]. Diazoxide transiently induces increased
ROS production [43,131–133], which is in agreement with the view
that mitochondria-derived reactive oxygen species are involved in
cardioprotective signaling during ischemic and pharmacological
preconditioning (overview in [8,39,40]). Importantly, diazoxide
and ischemic preconditioning associated ROS production is attenuat-
ed by myxothiazol [132,134], which clearly indicates that the Qo site
of complex III is the source. This site has been considered as a source
for mitochondria-derived ‘signaling ROS’ in several cellular process-
es including the stabilization of the hypoxia-inducible factor 1-α
[135–137]. In isolated rat heart mitochondria, complex II inhibitors
can increase the superoxide production at the Qo site of complex III
only under the speciﬁc conditions indicated in Section 3.2 and
Fig. 3B [15,16,33], i.e. when succinate is the predominant substrate
and under conditions of ‘oxidant-induced reduction’. This might ex-
plain why a ROS-increasing effect of diazoxide has not been detected
in the presence of NADH-generating substrates or when complex III
was not inhibited [129,138,139]. However, it has to be pointed out
that a physiological correlate of the experimentally induced
antimycin A inhibition has not been identiﬁed yet [25]. Hence, it is
uncertain whether this mechanism correctly describes ROS genera-
tion in vivo. Alternatively, diazoxide that probably binds to the Qp
site of complex II (unpublished results) might directly induce ROSgeneration at the FAD at relatively low succinate concentrations
(Fig. 3C). But this also has still to be shown experimentally.
4.3. Is a mitochondrial KATP channel involved in cardioprotective
preconditioning?
It was concluded frommany investigations that diazoxide targets
a mitochondrial form of ATP-dependent K+ channels (mitoKATP)
and that this channel plays a central role in cardioprotection by is-
chemic and pharmacological preconditioning and by ischemic
postconditioning [140–142]. However, the existence of such a
mitoKATP channel is controversial [8,39,142–144]. Especially, the
fact that the KATP channel subunits could not be identiﬁed so far in
highly puriﬁed mitochondria challenges its existence [145,146].
Furthermore, the selectivity of the drugs that are generally used
for the pharmacological characterization of the putative mitoKATP
channel is limited. Diazoxide inhibits complex II [128,129,147],
while the KATP channel antagonist 5-HD can be metabolized by the
ß-oxidation pathway of the mitochondria [148–150]. It has been
pointed out that the effects of diazoxide on mitochondrial respira-
tion occur at concentrations that are above the concentrations that
are usually applied for mitoKATP opening [151]. However, there is
general uncertainty whether the applied concentration in various
test systems will result in similar effective concentrations, which
might be largely inﬂuenced by the partition coefﬁcient and relative
membrane permeability of the applied drug. Therefore, several in-
vestigators have concluded that diazoxide and related substances
exert their effect independently of a mitoKATP channel by altering
mitochondrial respiration [42,128–130,133,152–155]. Recently, a
model was presented that merges these two conﬂicting views, i.e.
that complex II may be a component or regulator of the mitoKATP
channel [44,156,157]. Importantly, the results of Wojtovich and
Brookes indicate that the highly potent and speciﬁc complex II inhibitor
atpenin A5had the same cardioprotective effects in cardiomyocytes and
Langendorff-perfused rat hearts as ischemic preconditioning, diazoxide,
and malonate [44]. The effect of atpenin A5 was independent of com-
plex II inhibition, and the authors suggested that opening of the puta-
tive mitoKATP channel is the underlying mechanism. However, higher
concentrations of atpenin A5 – that were shown to inhibit complex II
activity – had to be used in Langendorf-perfused hearts to induce a
cardioprotective effect [44]. Hence, an alternative hypothesis was
presented that relates the cardioprotective effects of atpenins to
the modulation of mitochondrial ROS production [16]. We could
show in investigations with isolated rat heart mitochondria, that
the succinate-driven superoxide production at complex I by RET can
be abolished completely by atpenin A5 concentrations of 10 nM, a con-
centration that only partially inhibited succinate-dependent respiration
[16]. This can be explained by the pronounced sensitivity of RET toward
small changes inΔΨ [18]. In addition, similar atpenin A5 concentrations
stimulated the superoxide production at the Qo site of antimycin A
inhibited complex III, which may represent the source of ‘signaling
ROS’during ischemic and pharmacological preconditioning [15]. Impor-
tantly, the modulation of mitochondrial ROS production was indepen-
dent of K+-ions, indicating that a putative mitoKATP channel was not
involved.
5. Conclusions and outlook
There is increasing evidence that complex II (succinate:ubiqui-
none oxidoreductase) can be a major regulator of mitochondrial
ROS production under physiological and pathophysiological circum-
stances. In doing so, complex II can adapt different roles as a produc-
er or modulator of mitochondrial ROS depending on substrate supply
and the activities of the other respiratory chain complexes and TCA
cycle enzymes. The multifaceted function requires a careful analysis
of the complex II related ROS production with the available tools
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ously identify the source of ROS. This should help to understand
the role of complex II in different pathophysiological settings, in-
cluding ischemia/reperfusion injury. Future investigations should
focus more on the dual functions of complex II as a component of
the respiratory chain and the TCA cycle, since especially oxaloacetate
might be a main endogenous regulator of complex II activity. Finally,
basic mechanisms of ROS production by complex II can be further an-
alyzed in different model organisms including bacterial SQRs and
QFRs that have already been used for structure–function investiga-
tions and the analysis of disease-related human mutations.
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